Company Name, Ticker, Industry, else..

Nucana Plc (NASDAQ: NCNA)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Nucana Plc's

Name: Nucana Plc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NCNA Sales vs. its Competitors Q4 2025

Comparing the current results to its competitors, Nucana Plc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.9 %, recorded in the same quarter.

• List of NCNA Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Nucana Plc recorded a net loss, despite income increase by most of its competitors of 0 %

<< NCNA Stock Performance Comparisons

Nucana Plc's Comment on Competition and Industry Peers

The company operates in a competitive environment where other entities may discover, develop, or commercialize similar or identical products before or more successfully than it does. Its ability to compete is influenced by the adequacy of its intellectual property protection. Additionally, the company faces competition in integrating AI technologies, as competitors or third parties may implement AI into their products more rapidly and effectively. These factors may impact the company's competitive position and financial performance.

<< See the full list of NCNA competitors

*Market share is calculated based on total revenue.

NCNA's Stock Performance relative to its Competitors

Publicly Traded Peers of Nucana Plc

Zai Lab Limited
Share Performance

+46.25%

This Quarter

Zai Lab Limited

Profile

Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.

More about Zai Lab Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 28,963.120 mill.	$ 449.614 mill.	$ -188.213 mill.

Mersana Therapeutics inc
Share Performance

+273.56%

This Quarter

Mersana Therapeutics inc

Profile

Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.

More about Mersana Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 145.286 mill.	$ 33.180 mill.	$ -70.081 mill.

Kezar Life Sciences Inc
Share Performance

+15.90%

This Year

Kezar Life Sciences Inc

Profile

Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.

More about Kezar Life Sciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 53.537 mill.	$ - mill.	$ -45.233 mill.

Janux Therapeutics Inc
Share Performance

-31.39%

One Year

Janux Therapeutics Inc

Profile

Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.

More about Janux Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,053.570 mill.	$ 24.000 mill.	$ -102.592 mill.

Iovance Biotherapeutics inc
Share Performance

+316.47%

This Year

Iovance Biotherapeutics inc

Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,724.734 mill.	$ 324.969 mill.	$ -289.517 mill.

39 more competitors available

Sources: Nucana Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 4:04 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nucana Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.